-The Stroke Advisory Board brings together distinguished experts in neurology and stroke to support the advancement of its neural exosome platform and lead program– -Phase 1b/2a clinical trial in acute ischemic stroke expected to initiate in 2H 2024; AB126 is the first exosome to enter in human clinical trials for a neurological indication- BOSTON and ATHENS, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative diseases, is pleased to announce the formation of its Stroke Advisory Board (SAB).

-中风咨询委员会汇集了神经病学和中风领域的杰出专家，以支持其神经外泌体平台和领导计划的进展-预计于2024年下半年启动的急性缺血性中风1b/2a期临床试验；AB126是第一个进入人类神经系统适应症临床试验的外泌体-波士顿和雅典，佐治亚州，2024年3月4日（环球新闻网）-Aruna Bio，Inc.，一家基于神经外泌体的治疗神经退行性疾病的领导者，很高兴宣布成立其中风咨询委员会（SAB）。

Comprising distinguished experts in fields of neurology, stroke research, and clinical development, the board underscores Aruna Bio’s commitment to advancing its clinical development program with unparalleled expertise. The newly established board features renowned figures in the medical and scientific community, each bringing a wealth of knowledge and experience to Aruna Bio.

该委员会由神经病学，中风研究和临床开发领域的杰出专家组成，强调Aruna Bio致力于以无与伦比的专业知识推进其临床开发计划。新成立的董事会拥有医学和科学界的知名人士，每个人都为Aruna Bio带来了丰富的知识和经验。

The Phase 1b/2a clinical trial for acute ischemic stroke is expected to initiate in the second half of 2024, and the SAB’s strategic guidance will play a pivotal role as the company advances through clinical development. “AB126 is making history with the first exosome therapy to enter human clinical trials for a neurological condition,” said Stephen From, Chief Executive Officer at Aruna Bio.

急性缺血性卒中的1b/2a期临床试验预计将于2024年下半年启动，随着公司通过临床开发取得进展，SAB的战略指导将发挥关键作用。Aruna Bio首席执行官Stephen From说：“AB126是第一个进入人类神经系统疾病临床试验的外泌体疗法，创造了历史。”。

“This represents a significant step forward in our quest to transform the treatment landscape for stroke and other neurodegenerative diseases. We look forward to leveraging the collective expertise of our esteemed SAB members through this next stage of development and beyond. In parallel, we continue to explore broader applications of our platform across a range of inflammatory and neurodegenerative diseases.” Aruna SAB member bios.

“这是我们在寻求改变中风和其他神经退行性疾病治疗格局方面迈出的重要一步。我们期待着在下一个发展阶段及其后利用我们尊敬的SAB成员的集体专业知识。与此同时，我们继续探索我们平台在一系列炎症和神经退行性疾病中的更广泛应用治疗性疾病。”阿鲁纳SAB成员bios。